We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer.
- Authors
Hee Seung Kim; Mi-Kyung Kim; Hak Jae Kim; Seung-Su Han; Jae Weon Kim
- Abstract
Purpose This study investigated the efficacy and toxicity associated with consolidation chemotherapy using paclitaxel and carboplatin after concurrent chemoradiation (CCR) in cervical cancer patients. Materials and Methods From a total of 37 patients, 19 with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIA cervical cancer (group 1) underwent surgery followed by consolidation chemotherapy after CCR, and 18 with stage IIB-IVA disease (group 2) received consolidation chemotherapy after primary CCR. Three cycles of chemotherapy using paclitaxel (135 mg/m²) and carboplatin (AUC 5.0) were administered every 3 weeks for CCR therapy, and three cycles of consolidation chemotherapy using paclitaxel (175 mg/m²) and carboplatin (AUC 5.0) were used every 3 weeks after CCR. Results The complete and partial response rates were 77.8% and 22.2% in group 2. Moreover, the 3-year progression-free and overall survival rates were 62.7% and 90.9% in group 1, and 51.9% and 60% in group 2, respectively. The most common grade 3 or 4 hematologic toxicities observed were leukopenia (group 1,10.5%; group 2,13.0%) and neutropenia (group 1,7.0%; group 2,14.8%), and grade 3 or 4 diarrhea (group 1,1.8%) and febrile illness (group 2,1.9%) were the most frequently observed non-hematologic toxicities. When we compared these results with previous reports, consolidation chemotherapy after CCR using paclitaxel and carboplatin revealed a relatively lower complete response rate (77.8% vs. 87-100%, respectively) and shorter progression-free survival (51.9-62.7% vs. 81-86%, respectively) and overall survival (60-90.9% vs. 81-95%, respectively) in spite of similar toxicity findings. Conclusion Due to low efficacy results, consolidation chemotherapy using paclitaxel and carboplatin after CCR is not a feasible treatment regimen for high-risk early-stage or locally advanced cervical cancer.
- Subjects
CERVICAL cancer treatment; CANCER chemotherapy; ADJUVANT treatment of cancer; PACLITAXEL; CARBOPLATIN; THERAPEUTICS; CONSOLIDATION chemotherapy
- Publication
Cancer Research & Treatment, 2012, Vol 44, Issue 2, p97
- ISSN
1598-2998
- Publication type
Article
- DOI
10.4143/crt.2012.44.2.97